Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Pahl

Showing results (51-60 of 56) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 56 results.
Nature|August 26, 2021
Author Correction: TP53 loss creates therapeutic vulnerability in colorectal cancerYunhua Liu, Xinna Zhang, Cecil Han, et al.
Nature|April 23, 2015
TP53 loss creates therapeutic vulnerability in colorectal cancerYunhua Liu, Xinna Zhang, Cecil Han, et al.
Blood Advances|June 27, 2020
CRISPR-based screens uncover determinants of immunotherapy response in multiple myelomaPoornima Ramkumar, Anthony B Abarientos, Ruilin Tian, et al.
Cancer Research Communications|October 23, 2024
ETx-22, a Novel Nectin-4-Directed Antibody-Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4-Expressing TumorsMarc Lopez, Emerence Crompot, Emmanuelle Josselin, et al.
Gastroenterology|July 25, 2021
AGR2-Dependent Nuclear Import of RNA Polymerase II Constitutes a Specific Target of Pancreatic Ductal Adenocarcinoma in the Context of Wild-Type p53Zhiheng Zhang, Hongzhen Li, Yibin Deng, et al.
Acta Physiologica (Oxford, England)|February 27, 2026
pH-Dependent Microenvironmental Ionic Signaling in Pancreatic Ductal AdenocarcinomaAlbrecht Schwab, Micol Rugi, Pawel Swietach, et al.
Pageof 6

Showing results (51-60 of 56) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 56 results.
Nature|August 26, 2021
Author Correction: TP53 loss creates therapeutic vulnerability in colorectal cancerYunhua Liu, Xinna Zhang, Cecil Han, et al.
Nature|April 23, 2015
TP53 loss creates therapeutic vulnerability in colorectal cancerYunhua Liu, Xinna Zhang, Cecil Han, et al.
Blood Advances|June 27, 2020
CRISPR-based screens uncover determinants of immunotherapy response in multiple myelomaPoornima Ramkumar, Anthony B Abarientos, Ruilin Tian, et al.
Cancer Research Communications|October 23, 2024
ETx-22, a Novel Nectin-4-Directed Antibody-Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4-Expressing TumorsMarc Lopez, Emerence Crompot, Emmanuelle Josselin, et al.
Gastroenterology|July 25, 2021
AGR2-Dependent Nuclear Import of RNA Polymerase II Constitutes a Specific Target of Pancreatic Ductal Adenocarcinoma in the Context of Wild-Type p53Zhiheng Zhang, Hongzhen Li, Yibin Deng, et al.
Acta Physiologica (Oxford, England)|February 27, 2026
pH-Dependent Microenvironmental Ionic Signaling in Pancreatic Ductal AdenocarcinomaAlbrecht Schwab, Micol Rugi, Pawel Swietach, et al.
Pageof 6